<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130195</url>
  </required_header>
  <id_info>
    <org_study_id>JALSG Ph+ALL202</org_study_id>
    <nct_id>NCT00130195</nct_id>
  </id_info>
  <brief_title>Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)</brief_title>
  <official_title>Phase 2 Study of Imatinib-Combined Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Adult Leukemia Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Japan Adult Leukemia Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the clinical efficacy and safety of
      imatinib-combined chemotherapy on newly diagnosed BCR-ABL-positive ALL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Philadelphia chromosome (Ph) is a translocation abnormality leading to the formation of the
      BCR-ABL gene rearrangement. This genetic abnormality occurs in up to 30% of adult acute
      lymphoblastic leukemia (ALL), and its presence is known to be the most adverse prognostic
      factor for ALL. Because long-term survival cannot be achieved by conventional chemotherapy
      alone, there is a clear medical need for alternative treatment approaches. Imatinib is a
      potent selective inhibitor of the BCR-ABL protein kinase, and it has been reported that
      single-agent imatinib induced response in a substantial proportion of Ph-positive ALL
      (Ph+ALL) patients, but that the response was not durable. The Japan Adult Leukemia Study
      Group (JALSG) has therefore started a phase 2 study designed to evaluate the clinical effect
      of imatinib-combined chemotherapy on newly diagnosed BCR-ABL-positive ALL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of complete remission</measure>
    <time_frame>63 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of remission</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity caused by combination of imatinib and chemotherapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated BCR-ABL-positive ALL

          -  Age between 15 and 64 years

          -  Performance status between 0 and 3 (ECOG criteria)

          -  Adequate functioning of the liver (serum bilirubin level &lt; 2.0 mg/dL), kidneys (serum
             creatinine level &lt; 2.0 mg/dL), and heart (left ventricular ejection fraction greater
             than 50% and no severe abnormalities detected on electrocardiograms and
             echocardiographs)

          -  Written informed consent to participate in the trial

        Exclusion Criteria:

          -  Uncontrolled active infection

          -  Another severe and/or life-threatening disease

          -  Positive for HIV antibody and/or hepatitis B surface (HBs) antigen tests

          -  Another primary malignancy which is clinically active and/or requires medical
             interventions

          -  Pregnant and/or lactating women

          -  Past history of renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fumihiko Hayakawa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nagoya University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tomoki Naoe, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nagoya University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology, Nagoya University Graduate School of Medicine</name>
      <address>
        <city>Nagoya</city>
        <zip>466-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jalsg.jp/</url>
    <description>The JALSG homepage</description>
  </link>
  <results_reference>
    <citation>Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, Yagasaki F, Kawai Y, Miyawaki S, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2004 Dec 1;104(12):3507-12. Epub 2004 Aug 17.</citation>
    <PMID>15315963</PMID>
  </results_reference>
  <results_reference>
    <citation>Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006 Jan 20;24(3):460-6. Epub 2005 Dec 12.</citation>
    <PMID>16344315</PMID>
  </results_reference>
  <results_reference>
    <citation>Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Nishii K, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica. 2008 Feb;93(2):287-90. doi: 10.3324/haematol.11891. Epub 2008 Jan 26.</citation>
    <PMID>18223280</PMID>
  </results_reference>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2005</study_first_submitted>
  <study_first_submitted_qc>August 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2005</study_first_posted>
  <last_update_submitted>November 13, 2008</last_update_submitted>
  <last_update_submitted_qc>November 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2008</last_update_posted>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>BCR-ABL</keyword>
  <keyword>Philadelphia-chromosome</keyword>
  <keyword>newly diagnosed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

